MHRA statements, read directly

Anyone quoting an eligibility threshold should say which document it comes from. The thresholds have changed and the old ones are still circulating.

Two claims get bundled together under MHRA statements and they need separating. The descriptive one — this is what was observed — is usually well supported. The causal one — this is why — usually is not.

Almost every disagreement in threads like this one dissolves once you say which of the two you are making.

Adding the measurement that post #15 says would settle it.

I changed my mind about MHRA statements after someone here asked me for the source and I could not produce one. That is worth saying out loud because it is the ordinary way it happens.

Nothing in this subcategory is medical or legal advice, and prescribers reading here consistently say so themselves.

Adding a data point of agreement rather than a data point.

Coming back to post #16, because the follow-up matters more than the original answer.

The relevant national body publishes its decisions and its shortage notifications directly, and those are the primary sources rather than any secondary summary.

That is all I can say without guessing.

I keep a log for MHRA statements specifically because my memory of it turned out to be systematically wrong in one direction. Six weeks of notes cost nothing and settled it.

MHRA is the regulator. Licensed incretin analogues are prescription-only medicines. NHS and private prescribing routes exist with materially different access criteria and costs.

I would call that likely rather than established.

Before the thread moves on from MHRA statements — what is the sample size behind the claim? I am not being difficult; I have seen the same figure quoted from an n of four and from an n of four hundred.

That matches what I have seen, for whatever a single anecdote is worth.

Where I part company with post #21, and it is a narrow parting.

A referral pathway that worked eighteen months ago may not exist now. The archive keeps these posts and they are read as current.

I would rather post the uncertainty than round it away.

Adding the boring version of MHRA statements, because the interesting version keeps getting posted and the boring one is usually right.

Check the ordinary explanations, in order, and stop when one of them accounts for what you are seeing. Most of the time the second one does.

Where the compound is supplied with a device, the device and the compound have separate availability positions and the device is more often the constraint.

Post #25 put the caveat in the right place and I want to underline it.

The useful distinction on MHRA statements is between what was measured and what was inferred from it. Both end up in the same sentence and only one of them has error bars.

Building on post #29 rather than restating it.

Where guidance distinguishes between indications, quoting the indication is essential. The same compound has different positions under different indications.

A guess, clearly labelled as one.